Novo's Growth Recovery Has a Bridge Under It

Q3 beat and another guidance raise mask a U.S. GLP-1 franchise leaning on Medicare's Bridge program — and a CFO handoff just before the 2027 guide

NVO · Earnings Call · 2026-11-04

Novo's Growth Recovery Has a Bridge Under It

Novo Nordisk's Q3 2026 call arrived with the right headline: adjusted sales rose 4% to DKK 79.2 billion, adjusted operating profit rose 27%, and management raised full-year guidance again, now -2% to +2% for both adjusted sales and operating profit at constant exchange rates, with free cash flow of DKK 60 billion to DKK 70 billion. The CEO's framing was deliberately steady: “The quarterly development clearly shows that we are at the growth recovery phase, and that is progressing well.” — Mike Doustdar, Chief Executive Officer (CEO) · 2026-11-04 After a stock that has fallen more than 60% over two years and trades at 11.8x forward earnings, that is the message Novo needs investors to believe. But the mix is less clean than the headline. U.S. operations grew only 1% in the quarter; International Operations grew 8%, with EUCAN up 18%. Obesity sales rose 22%, and Novo now says it reaches about 48 million people with diabetes and obesity treatments, including 5.6 million in obesity, nearly double a year ago. The growth is real. The question is how much of it is durable demand versus a policy bridge and price investment.

The Bridge Program Is the Load-Bearing Keyword

The company's freshest keyword is not a molecule. It is the Bridge program — the Medicare demonstration that has become the clearest driver of U.S. GLP-1 volume. Jamey Millar said Bridge is running at about 60,000 TRx per week across injectable and oral, and that the 20% sequential growth in Wegovy pill volume was largely, though not exclusively, Bridge. Then he said the quiet part out loud:

Without the Bridge contribution, there is less growth than the 20% sequential growth that we talked about. Bridge is definitely creating an inflection in the category, and without Bridge, the AOM category, not just Novo, but the category, looks relatively flat in the May to October timeframe, reflecting the seasonality.
Jamey Millar, Executive Vice President, U.S. Operations · 2026-11-04

That is the central tension of the report. Novo's U.S. recovery is not yet broad commercial demand; it is a policy-supported volume bridge in a category that is otherwise flat ex-Bridge. Management is already trying to turn Bridge into a 2027 tailwind by annualizing it: “The pluses for us next year is the continued Wegovy pill uptake in U.S. and IO... The other plus is we have seen a good uptake in U.S. Bridge Program. That program started mid this year, so you need to annualize it” — Mike Doustdar, Chief Executive Officer (CEO) · 2026-11-04. The problem is that Bridge ends at the end of 2027. Jamey was candid that payer reticence is now about the cost trend, not just price: “the reticence on behalf of the downstream payers, employers, government, private payers, is increasingly about the volume concern side of the equation” — Jamey Millar, Executive Vice President, U.S. Operations · 2026-11-04. He name-checked Pepsi and Starbucks as employers that move against the cost trend. Bridge may be a bridge to 2027, but it is not yet a bridge to broad commercial coverage. This is where prior calls matter. In February, Karsten Munk Knudsen described Medicare Part D as a gradual unlock: “it will be a gradual ramp with limited benefit this year and a bigger benefit into 2027” — Karsten Knudsen, Executive Vice President, Finance · 2026-02-04. Nine months later, that gradual ramp has become the load-bearing element of U.S. growth. The guidance raise is real, but the quality of the beat depends on a program with a political expiration date.

What Disappeared From the Script

The more interesting change is what Novo stopped talking about. In 2025 and early 2026, compounded GLP-1 was a top-of-mind theme on nearly every call — the illegal importation fight, the May 22 enforcement date, the cash channel, the telehealth partnerships. Dave Moore was explicit in November 2025: “as of May 22, compounding is illegal in the U.S. except for rare circumstances” — David S. Moore, Unknown (likely Commercial or Sales Executive based on context) · 2025-08-06. In the current transcript, compounding barely exists. The language has moved to Bridge, capture rates, payer cost trends and oral competition. That is not because the issue was solved; it is because the battlefield shifted from legal enforcement to payer economics and product competition. The same is true of the Metsera bid and the FTC questions that dominated the prior-year Q3 Q&A. They are absent here. So is the old obsession with REDEFINE 4 as the binary CagriSema-versus-tirzepatide readout. Novo now talks about CagriSema through REIMAGINE 5, REDEFINE 9 and the women's-health analyses. The pipeline narrative has moved from "can CagriSema match tirzepatide?" to "here is the evidence at lower doses, and here is the launch." That is a healthier story, but it also means the market has lost a clean binary catalyst.

The New Launch Stack: Oral, High Dose, CagriSema

The current call's product keywords tell the next chapter: Ozempic pill, Wegovy HD and brand prescription share. In the U.S., Wegovy pill is capturing around 80% of new-to-brand oral obesity prescriptions and has more than eight million cumulative prescriptions since launch. Ozempic pill's transition from Rybelsus is complete, and more than 60% of its new-to-brand prescriptions are from GLP-1-naive patients. That is genuine market expansion, not just switching. But Jamey also flagged the low capture rate from IQVIA because Novo's partner ecosystem does not fully report. The headline script number may understate the pill; it also makes the competitive comparison less clean. Wegovy HD is a smaller but telling lever: about 20,000 prescriptions a week, roughly 5% of total U.S. Wegovy volume, with 80% of those scripts titrating up from 2.4 mg. Novo's argument is that those are scripts otherwise lost to the franchise. Internationally, the pill is in seven markets, with roughly 90% oral-obesity share in the U.K. and 80% in the UAE, and about 100,000 packs sold in Germany in six weeks. Management now expects more than 20 markets by the first half of 2027. CagriSema is the bigger 2027 swing. In REIMAGINE 5, CagriSema at 1 mg of each component delivered 12.4% weight loss versus 9.1% for tirzepatide 5 mg, with non-inferior A1c reduction. REDEFINE 9 showed 21% weight loss at 68 weeks at the lower maintenance dose. The post-hoc women's analyses showed average 25% weight loss, with 27%, 25% and 23% across pre-, peri- and post-menopausal groups. That explains why women became a fresh keyword in the quarter. Mike Doustdar was careful not to overclaim a Wegovy halo for CagriSema: he called it medium, not high, because amylin makes it more than semaglutide. The launch, plus Frehemgo in hemophilia, is the 2027 growth story management wants investors to underwrite.

The CFO Handoff and the 2027 Setup

The report also marks a governance transition. Karsten Munk Knudsen is leaving after 27 years, and Luigi La Corte joins from Galderma as CFO. Mike praised Karsten's nine years as CFO and said he will stay through year-end for a smooth transition. The timing matters because Novo is about to guide 2027 with a new finance chief. Management gave building blocks, not guidance: pluses from Wegovy pill, Bridge annualization, CagriSema and Frehemgo; minuses from international LOE, China — still declining 2% and facing LOE next year — and the favorable gross-to-net in 2026 that will not repeat. Karsten had already warned in November 2025 that the gross-to-net benefit was about 2 percentage points and would not repeat. The current call repeats that warning, but now the messenger is leaving. The stock's problem has never been whether GLP-1 demand exists. It is whether Novo can convert demand into durable, profitable growth while its U.S. franchise leans on a temporary Medicare bridge and its oral franchise runs through partners that blur the script data. Q3 says the recovery is real. The Bridge program says it is not yet self-sustaining. The next two quarters — the 25 mg Ozempic pill approval, the CagriSema launch, and the 2027 guide under a new CFO — will determine whether this is a turn or another policy-aided plateau.